Clinical Trials Directory

Trials / Terminated

TerminatedNCT02552732

Nasal High Flow Therapy 30 Day Readmission Study

Nasal High Flow (NHF) Therapy Use Following Hospitalization for an Exacerbation of COPD: A Feasibility Study

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
29 (actual)
Sponsor
Fisher and Paykel Healthcare · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of this feasibility study is to provide data for a subsequent randomized controlled trial to investigate if patient outcomes will be improved after an acute COPD exacerbation using domiciliary nasal high flow therapy (NHF) compared to standard care. This feasibility study will investigate the following: process, resources, management and scientific aspects of delivering NHF as an adjunct therapy in COPD patients.

Conditions

Interventions

TypeNameDescription
DEVICENHF with or without OxygenNHF using myAIRVO™ 2 will be set at 25L/min at 37°C. However, all participants are able to lower the delivered temperature to 34°C.

Timeline

Start date
2015-11-01
Primary completion
2017-05-03
Completion
2017-05-03
First posted
2015-09-17
Last updated
2020-08-17
Results posted
2020-07-24

Locations

2 sites across 2 countries: United States, New Zealand

Source: ClinicalTrials.gov record NCT02552732. Inclusion in this directory is not an endorsement.

Nasal High Flow Therapy 30 Day Readmission Study (NCT02552732) · Clinical Trials Directory